T-Therapeutics

Executive Summary

T-Therapeutics is a UK-based biotechnology company pioneering next-generation T cell receptor (TCR)-based therapies to address key limitations in immuno-oncology. Founded in 2020 as a spin-out from the University of Cambridge, the company leverages world-leading academic expertise in immunology and genome engineering to develop highly specific TCR drugs that direct a patient's own T cells to recognize and eliminate tumors. By focusing on TCRs, T-Therapeutics aims to expand the therapeutic window beyond current checkpoint inhibitors and CAR-T therapies, targeting a broader range of solid tumors with improved safety and efficacy. The company's platform combines advanced TCR discovery, engineering, and validation to generate optimized candidates with high specificity and potency, potentially unlocking new treatment options for patients with high unmet need. While still in early stages, T-Therapeutics has established a strong scientific foundation and is building toward key inflection points. The company has not disclosed funding or pipeline specifics publicly, but its focus on TCR-based modalities positions it in a rapidly growing field with significant investor interest. With a robust platform and clear translational pathway, T-Therapeutics is poised to advance its lead candidates toward preclinical and early clinical development. The upcoming milestones, including preclinical validation and potential financing, will be critical in demonstrating the platform's potential and driving value creation for stakeholders.

Upcoming Catalysts (preview)

• Q2 2027Preclinical Proof-of-Concept Data for Lead TCR Candidate60% success
• Q3 2026Series A Financing Round70% success
• Q4 2028First IND Filing for Lead Program40% success